AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

Expert Review of Vaccines, published by Taylor & Francis Ltd, is a pivotal open access journal that has established itself as a leading source of peer-reviewed articles focusing on vaccine research, development, and policy. With an impressive categorization in the top quartile (Q1) across various domains including Drug Discovery, Immunology, Molecular Medicine, and Pharmacology for 2023, this journal plays a crucial role in disseminating high-quality scientific findings that drive advances in the field. Located in the United Kingdom, it serves a global audience of researchers, healthcare professionals, and students seeking to stay abreast of cutting-edge developments in vaccination strategies and technologies. The journal’s Scopus ranks further attest to its excellence, boasting remarkable placements in Pharmacology and Drug Discovery, reflecting its impact and reach. Since transitioning to an open access format in 2023, the journal has enhanced accessibility to vital research, empowering a broader audience to contribute to and engage with the discourse surrounding vaccines. As the field of immunization continues to evolve, Expert Review of Vaccines remains a cornerstone for those committed to advancing knowledge and practice in this essential area of health science.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

Vaccines, published by MDPI in Switzerland, is a leading open access journal that has been at the forefront of vaccine research since its inception in 2013. With an impressive impact factor and consistently ranked in the Q1 and Q2 quartiles across leading categories such as Drug Discovery, Immunology, Infectious Diseases, and Pharmacology, it provides a vital platform for researchers to share their findings and advance the field. The journal is dedicated to delivering high-quality original research articles, reviews, and case studies that address the challenges and innovations in vaccine development and immunization strategies worldwide. Open access since its launch, Vaccines ensures that cutting-edge research is widely available to the global academic community and public health professionals, thereby fostering collaboration and enhancing knowledge in this critical area of public health.

Tropical Diseases Travel Medicine and Vaccines, published by SPRINGERNATURE, stands at the forefront of research in the fields of infectious diseases and public health, with an impressive impact factor that signifies its relevance and influence. Since its inception in 2015, this peer-reviewed journal has maintained an open access policy, ensuring that cutting-edge research on tropical diseases and travel medicine is readily available to researchers, professionals, and students worldwide. The journal currently ranks in the Q2 Quartile for both Infectious Diseases and Public Health, Environmental and Occupational Health, reflecting its substantial contribution to these critical areas of study. With a strong Scopus rank of #176 in Public Health and #138 in Infectious Diseases, it serves as a vital platform for innovative studies that advance understanding and response strategies related to tropical diseases. For its vast audience, Tropical Diseases Travel Medicine and Vaccines not only acts as a bridge connecting researchers with practical applications but also nurtures academic discourse essential for future advancements in global health.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.